

Safety of JAK Inhibitors in the Treatment of Inflammatory Skin Diseases

Saturday, June 1, 2024 • 08:30-10:00 am CEST Feria Valencia • Hall Barcelona • València, Spain

An International Eczema Council Symposium at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Congress

AGENDA

08:30-08:40

Welcome from the IEC & Program Overview

Alan Irvine, MD DSc, Dublin, Ireland

08:40-09:00

Mechanisms and Consequences of JAK-STAT Signaling in the Immune System

Ioana Agache, MD PhD, Brașov, Romania

09:00-09:20

The Experience from Clinical Trials

Alan Irvine, MD DSc, Dublin, Ireland

09:20-09:40

The Real-World Data

Marjolein de Bruin-Weller, MD PhD, Utrecht, The Netherlands

09:40-09:55

Presenter Panel Discussion & Audience Q&A

all presenters

09:55-10:00

Closing Comments & Adjourn

Ioana Agache, MD PhD, Brașov, Romania

PROGRAM CO-CHAIRS



Alan Irvine, MD DSC, IEC President

Alan Irvine has been a consultant dermatologist at Children's Health Ireland and St. James's Hospital, Dublin, Ireland, since 2002 and professor of dermatology at Trinity College Dublin since 2007. He became the IEC president earlier this year.

He has published extensively in high impact journals such as the New England Journal of Medicine, The Lancet, Nature Genetics, and Nature Reviews Disease Primers—mostly on epithelial genetics, characterisation of the skin barrier, disease mechanisms in, and therapy of, atopic dermatitis. His international awards for research include the Times Higher Education Supplement Research Project of the Year and the Paul Gerson Unna Prize (German Dermatology Society). He has delivered several prize lectureships including the MB Sulzberger (AAD), Watson-Smith (RCP Edin), and Dolovich (AAAAI).

Dr. Irvine is a founding director of the International Eczema Council, an elected member of the Royal Irish Academy and the Academia Europaea, and an honorary member of the Société Française de Dermatologie.

He trained in dermatology and genetics in Belfast, Northern Ireland; in Great Ormond Street Hospital in London, England; and as a Fulbright Scholar at Children's Memorial/Northwestern University in Chicago, IL, USA.



Ioana Agache, MD PhD, IEC Councilor

Ioana Agache is professor of allergy and clinical immunology at Transylvania University in Braşov, Romania. She also is a past president (2017–2019) of the European Academy of Allergy and Clinical Immunology (EAACI).

Her research in the field of asthma, allergy, and clinical immunology focuses on asthma phenotypes and endotypes, immune modulation and immune tolerance, and integrated management of allergic diseases, with a special focus on primary care and community pharmacists.

Dr. Agache is leading development of the EAACI Biologics Guidelines. She is a member of the Steering Committee and co-author of several international and European guidelines, such as Allergic Rhinitis and its Impact on Asthma (ARIA), the EAACI Allergen Immunotherapy Guidelines, and the EAACI Food Allergy and Anaphylaxis Guidelines.

She is editor of several books including Implementing Precision Medicine in Best Practices of Chronic Airway Diseases (2018) Global Atlas of Asthma (2013), Global Atlas of Allergy (2014), and Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis (2015). She is associate editor of Clinical and Translational Allergy and a member of the editorial board for Allergy and the Journal of Allergy and Clinical Immunology.

Dr. Agache graduated with a medical degree from Carol Davila University of Medicine and Pharmacy in Bucharest and graduated magna cum laude with her PhD in internal medicine.

PROGRAM FACULTY



Marjolein de Bruin-Weller, MD PhD, IEC Councilor

Marjolein de Bruin-Weller is full professor and head of the National Expertise Center of Atopic Dermatitis in the Department of Dermatology and Allergology at the University Medical Center Utrecht in Utrecht, The Netherlands.

Her major interest is clinical and translational research in atopic dermatitis. She is the principal investigator in several clinical trials and investigator-initiated studies focused on difficult to treat atopic dermatitis and systemic immunosuppressive and immuno-modulating treatment.

In 2018, she initiated the BioDay Registry in the Netherlands together with Dr. Marie-Louise Schuttelaar from the Department of Dermatology at the University Medical Center of Groningen. This registry is focused on the new advanced systemic treatments in atopic dermatitis and includes a significant amount of data regarding atopic dermatitis (signs, symptoms, quality of life, work impairment) as well as data on atopic comorbidities. More than 1,900 patients from 18 sites in the Netherlands are included in the BioDay registry.

Together with Femke van Wijk, professor of tissue immunology at the Center of Translational Immunology (CTI) of the University Medical Center Utrecht, she leads the translational atopic dermatitis research group.

Dr. de Bruin-Weller is chair of the expertise group Allergy and Eczema of the Dutch Society of Dermatology and Venereology and a member of the European Task Force of Atopic Dermatitis (ETFAD) and the GA²LEN ADCARE Task Force. She is chair of the advisory board of the Dutch Patient Society for Atopic Dermatitis (VMCE) and member/chair of several Dutch committees regarding advanced systemic treatments in inflammatory diseases.





THE IEC BRINGS TOGETHER ALLERGISTS AND DERMATOLOGISTS

The IEC isn't just for dermatology specialists! Our Council consists of allergists and dermatologists who are passionate about furthering treatment of atopic dermatitis through education and research—whether they work in a clinical, research, or academic setting.

Together, our 133 Councilors and Associates from 31 countries improve patient care by promoting research, education, and best practices in the treatment for atopic dermatitis in people worldwide.

If our mission resonates with you, consider applying to join the Council as a Councilor or Associate.





IEC THANKS OUR CORPORATE SUPPORTERS

The support of our corporate partners makes it possible for the International Eczema Council (IEC) to advance its mission of improving patient care by promoting research, education, and best practices in treatment for atopic dermatitis in people worldwide.

Learn how to join these companies in advancing the IEC mission; visit <u>eczemacouncil.org/corporate-membership</u> and email CEO Alan Stiles at <u>astiles@eczemacouncil.org</u>.











ABOUT THE INTERNATIONAL ECZEMA COUNCIL

Founded in late 2014 and led by experts in atopic dermatitis, the International Eczema Council (IEC) is a global nonprofit organization. Dermatologists and allergists from around the globe serve as Councilors and Associates, contributing their expertise to support the IEC's research, programs, events, and education. The IEC has 133 Councilors and Associates in 31 countries, and this group continues to grow.

Mission

Improve patient care by promoting research, education, and best practices in treatment for atopic dermatitis in people worldwide.

Vision

Transforming the lives of people with atopic dermatitis.

Upcoming Symposia

<u>From Comparative Pathogenesis to Biomarker-Guided Treatments in Psoriasis and Eczema:</u> September 4 at ESDR in Lisbon, Portugal. Presented jointly with the International Psoriasis Council.

<u>Chronic Hand Eczema:</u> September 28 at EADV in Amsterdam, Netherlands.

Visit the Symposia Page



International Eczema Council

8735 W. Higgins Road, Suite 300 Chicago, IL 60631, USA 888.382.3724 (USA)

info@eczemacouncil.org EczemaCouncil.org

Contact IEC CEO Alan Stiles at astiles@eczemacouncil.org.

CONNECT WITH THE IEC ON SOCIAL MEDIA!







